Cytomegalovirus (CMV) Retinitis is caused by cytomegalovirus infection, which is a herpes-type virus that affects the retina of the human eye among patients having a weak immune system that could be due to conditions such as AIDS, leukemia and/or pregnancy. Symptomatic conditions include floaters, flashes, and blind spots besides loss of peripheral or blurred vision in the eyes of immune compromised patients.CMV infection often leads to hemorrhagic retinal inflammation along with vascular distribution. The CMV infection if left untreated spreads from one eye to the other, eventually leading to visual loss and/or complete blindness. Therefore, prompt diagnosis through blood as well as urine tests besides other optical tests that involve withdrawal of a small specimen fluid from the infected eye is recommended. 

Global CMV retinitis market can be segmented on the basis of anti-CMV drugs or anti-infective ophthalmic drugs into Foscarnet, Ganciclovir, Cidofovir, Fomivirsen and others. In the anti-CMV drugs segment, various off-label drugs are also being used, however many of these drugs have serious contraindications. In this market segment, one of the key challenges is drug resistance which needs to be counterfeited with clinical trials and pipeline drugs. For instance, intraocular Fomivirsen has been found to prevent CMV retinitis during clinical trials. Further, the CMV retinitis market can also be segmented on the basis of available therapeutic treatments into anti-CMV Oral Ganciclovir, anti-CMV Intravenous drug therapy, anti-CMV Intraocular (local), and anti-HIV Systemic and Retinal Detachment through Vitrectomy. Oral therapy is relatively more convenient and recommended for peripheral retinitis cases but not for later stages of CMV retinitis when the condition becomes visually threatening.

Intravenous therapy treats the infection along with protecting the eye against systemic infection. Furthermore, higher longevity has been observed with Foscarnet in comparison to Ganciclovir.  Intraocular therapy is highly effective in controlling infection, and is relatively less costly than systemic and superior to intravenous. However, intraocular implants need replacement after a duration of 6-8 months, especially among those having lower levels of T-helper cell counts. Systemic treatment is directed towards the HIV virus through a combination of reverse transcriptase and protease inhibitors, which is a highly active anti-retroviral therapy to restore immune system besides raising the T-helper cell counts.

Geographically, North America (U.S and Canada) dominate the CMV Retinitis market followed by Europe as leading manufacturers of CMV Retinitis are domiciled in these regions having majority of their operations in the local regional markets. However, Asia Pacific, Africa as well as Latin America would also prove to be the highly profitable markets in the future due to the high prevalence rates for immunodeficiency diseases in these regions. 

Taking into consideration the staggering figures of around 33,400,000 persons living with HIV infection, who are highly susceptible to the CMV retinitis condition globally, this specialized and niche market is estimated to escalate at a high pace. However, some of the restraints in this foresighted growth would include the newer anti-HIV medications, which prevent occurrence of this disease. Moreover, since this disease is largely concentrated to patients with pre-existing conditions such as HIV the overall size of the market will be smaller as CMV retinitis occur in approximately 46% of the HIV patients in comparison with other common diseases. 

Some of the major players that are currently operating in this market include Bausch & Lomb Incorporated, CSL Behring, Emcure Pharms, Ltd., Endo Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Hospira, Inc., Luitpold Pharmaceuticals, Inc., Mylan N.V., and Valeant Pharmaceuticals International, Inc. among others.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Cytomegalovirus Retinitis Market

Pre Book